CFO VoiceCFO Tribune ↗

Company · REGN · CIK 0000872589

Regeneron Pharmaceuticals

3 quotes from Regeneron Pharmaceuticals's finance chief, verbatim from the company's own earnings releases: Christopher Fenimore.

Who holds the CFO seat, from SEC filings: Regeneron Pharmaceuticals on CFO Tribune.

Quarters are the calendar quarter of the release date, not the company's fiscal quarter.

Q4 2026 releases

We are pleased with our third quarter financial results, which marked our third consecutive quarter of double-digit growth in both revenue and non-GAAP EPS
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron, Regeneron PharmaceuticalsRegeneron Reports Third Quarter 2026 Financial and Operating Results · October 30, 2026 · source: sec.gov · permalink

Q3 2026 releases

Second quarter revenues grew 17% and non-GAAP net income per share grew 11%, marking our second consecutive quarter of double-digit growth on both measures
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron, Regeneron PharmaceuticalsRegeneron Reports Second Quarter 2026 Financial and Operating Results · July 30, 2026 · source: sec.gov · permalink
By the end of the second quarter, we had fully repaid the Sanofi Development Balance, which represented the outstanding amount due to Sanofi for their funding of prior collaboration development activities.
Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron, Regeneron PharmaceuticalsRegeneron Reports Second Quarter 2026 Financial and Operating Results · July 30, 2026 · source: sec.gov · permalink

We publish quotes as the company released them and add no view on the company's results or shares. Spot an error? Send a correction.